Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324345 | 0.85 | P2RX3 (0.34) | P2RX3P2RX2MCOLN2CYP17A1CYP11B1 | |
| SCHEMBL26558669 | 0.85 | P2RX3 (0.34) | P2RX3P2RX2 | |
| SCHEMBL21347897 | 0.85 | MCOLN2 (0.36) | MCOLN2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL25463387 | 0.81 | TSHR (0.38) | MCOLN2CYP17A1CYP11B1CYP11B2TSHR | |
| SCHEMBL21041367 | 0.81 | P2RX3 (0.33) | P2RX3P2RX2CYP11B1CYP11B2TSHR | |
| SCHEMBL6640709 | 0.81 | MCOLN2 (0.35) | MCOLN2CYP17A1CYP11B1CYP11B2MALT1 | |
| SCHEMBL18595099 | 0.81 | TSHR (0.38) | MCOLN2CYP17A1CYP11B1CYP11B2TSHR | |
| SCHEMBL6644690 | 0.78 | CYP17A1 (0.34) | MCOLN2CYP17A1CYP3A4 | |
| SCHEMBL25719111 | 0.78 | CYP11B1 (0.37) | MCOLN2CYP11B1CYP11B2 | |
| SCHEMBL22661740 | 0.76 | CYP17A1 (0.33) | CYP17A1CYP11B1CYP11B2MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103360324-A | Novel pyrimidine derivatives and their use in perfume compositions | INT FLAVORS & FRAGRANCES INC | 2013-10-23 | — | — | CN | claimed |
| EP-2644688-A2 | Novel pyrimidine derivatives and their use in perfume compositions | International Flavors & Fragrances Inc. (US) | 2013-10-02 | — | — | EP | claimed |
| US-20120277325-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2012-11-01 | — | — | US | claimed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070173501-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173500-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173501-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173500-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | P2RX3 4141/4885P2RX2 4243/4885MCOLN2 3874/4885 |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | PBK, KLKB1, PIGK | P2RX3 3542/4885P2RX2 3952/4885MCOLN2 3077/4885 |
| US-20120277325-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS | DPYD, HINT1, MTR | P2RX3 40/4885P2RX2 35/4885MCOLN2 1367/4885 |
| US-20070010668-A1 | Pyrimidine compounds | TYMS, TYMP, DPYD | P2RX3 95/4885P2RX2 79/4885MCOLN2 4303/4885 |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | P2RX3 4389/4885P2RX2 4491/4885MCOLN2 2617/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | P2RX3 204/4885P2RX2 254/4885MCOLN2 4641/4885 |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | P2RX3 2404/4885P2RX2 3822/4885MCOLN2 4696/4885 |
| US-20070173501-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | DSTYK, CDK2, ERBB2 | P2RX3 3384/4885P2RX2 3305/4885MCOLN2 4725/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | P2RX3 4757/4885P2RX2 4825/4885MCOLN2 4691/4885 |
| US-20070173500-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | DSTYK, CDK2, ERBB2 | P2RX3 3384/4885P2RX2 3305/4885MCOLN2 4725/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | P2RX3 4435/4885P2RX2 4454/4885MCOLN2 1751/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | P2RX3 4352/4885P2RX2 4598/4885MCOLN2 4411/4885 |
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | P2RX3 4139/4885P2RX2 3977/4885MCOLN2 3638/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | P2RX3 816/4885P2RX2 746/4885MCOLN2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.